Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference

GlobeNewswire May 15, 2018

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference

GlobeNewswire May 14, 2018

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Benzinga.com  May 13, 2018

Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire May 8, 2018

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate Update

GlobeNewswire May 1, 2018

Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.

GlobeNewswire March 28, 2018

Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer

GlobeNewswire March 13, 2018

Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update

GlobeNewswire March 7, 2018

Xenon Pharmaceuticals Inc. to Host Earnings Call

ACCESS Newswire March 7, 2018

Xenon Pharmaceuticals Q4 Earnings Outlook

Benzinga.com  March 7, 2018

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update

GlobeNewswire February 28, 2018

Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial

GlobeNewswire February 20, 2018

Xenon Pharmaceuticals Outlines Key Milestones for 2018

GlobeNewswire January 8, 2018

Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting

GlobeNewswire December 4, 2017

Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

GlobeNewswire November 8, 2017

Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2017

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Provide Corporate Update

GlobeNewswire November 1, 2017

Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial

GlobeNewswire October 17, 2017

Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update

GlobeNewswire August 3, 2017

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update

GlobeNewswire July 27, 2017